Cited by 19Epilepsy research and treatmentPharmaceutical Practices and Patient OutcomesPharmacy and Medical Practices

Comprehensive educational plan for patients with epilepsy and comorbidity (EDU-COM): a pragmatic randomised trial

Beretta, S., Beghi, E., Messina, P., Gerardi, F., Pescini, F., La Licata, A., Specchio, L., Ferrara, M. +13 more·2014·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

BACKGROUND: The impact of educational strategies in the management of adverse treatment effects and drug interactions in adult patients with epilepsy with comorbidities remains undetermined. OBJECTIVE: The EDU-COM study is a randomised, pragmatic trial investigating the effect of a patient-tailored educational plan in patients with epilepsy with comorbidity. METHODS: 174 adult patients with epilepsy with chronic comorbidities, multiple-drug therapy and reporting at least one adverse treatment effect and/or drug interaction at study entry were randomly assigned to the educational plan or usual care. The primary endpoint was the number of patients becoming free from adverse treatment events and/or drug interactions after a 6-month follow-up. The number of adverse treatment events and drug interactions, health-related quality of life (HRQOL) summary score changes and the monetary costs of medical contacts and drugs were assessed as secondary outcomes. RESULTS: The primary endpoint was met by 44.0% of patients receiving the educational plan versus 28.9% of those on usual care (p=0.0399). The control group reported a significantly higher risk not to meet successfully the primary endpoint at the end of the study: OR (95% CI) of 2.29 (1.03 to 5.09). A separate analysis on drug adverse effects and drug interactions showed that the latter were more sensitive to the effect of educational treatment. Quality of life and costs were not significantly different in the two groups. CONCLUSIONS: A patient-tailored educational strategy is effective in reducing drug-related problems (particularly drug interactions) in epilepsy patients with chronic comorbidities, without adding significant monetary costs. Registered at ClinicalTrials.gov, identifier NCT01804322, (http://www.clinicaltrials.gov).

Integrity signals

Registry

Crossref · 10.1136/jnnp-2013-306553

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Beretta, S., Beghi, E., Messina, P., Gerardi, F., Pescini, F., La Licata, A., Specchio, L., Ferrara, M., Canevini, M. P., Turner, K., La Briola, F., Franceschetti, S., Binelli, S., Giglioli, I., Galimberti, C. A., Fattore, C., Zaccara, G., Tramacere, L., Sasanelli, F., Pirovano, M., & Ferrarese, C.
Affiliations
  • University of Milano-Bicocca (IT)
  • Mario Negri Institute for Pharmacological Research (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • University of Foggia (IT)
  • University of Milan (IT)
  • Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
  • Santa Maria Nuova Hospital (IT)
Corresponding author
Beretta, S.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2014-01-08
Volume
85
Issue
8
Pages
889-894
ISSN
0022-3050 (ISSN-L)
OpenAlex
W2136282551
Cited by
19
References
32
Citations by year
2025: 2 · 2024: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 4 · 2017: 6 · 2016: 1
FWCI
1.78
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
Keywords
epilepsy, comorbidities, patient education, drug interactions, adverse drug reactions, drug-related problems, multidrug therapy, health-related quality of life, health care costs
MeSH terms
Adolescent, Adult, Aged, Anticonvulsants, Data Interpretation, Statistical, Drug Interactions, Epilepsy, Female, Humans, Male, Middle Aged, Patient Education as Topic, Quality of Life, Socioeconomic Factors, Bias, Single-Blind Method, Treatment Outcome, Outcome Assessment, Health Care, Cost of Illness, Sample Size, Patient-Centered Care, Endpoint Determination, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review